HALCION Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Halcion, and what generic alternatives are available?
Halcion is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in HALCION is triazolam. There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the triazolam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Halcion
A generic version of HALCION was approved as triazolam by NOVAST LABS on October 20th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HALCION?
- What are the global sales for HALCION?
- What is Average Wholesale Price for HALCION?
Summary for HALCION
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 38 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,103 |
| Drug Prices: | Drug price information for HALCION |
| What excipients (inactive ingredients) are in HALCION? | HALCION excipients list |
| DailyMed Link: | HALCION at DailyMed |
Recent Clinical Trials for HALCION
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boston Medical Center | Phase 4 |
| Akili Interactive Labs, Inc. | N/A |
| Pfizer | Phase 1 |
Pharmacology for HALCION
| Drug Class | Benzodiazepine |
US Patents and Regulatory Information for HALCION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-003 | Apr 26, 1985 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-001 | Nov 15, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-002 | Nov 15, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HALCION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-003 | Apr 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-001 | Nov 15, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | HALCION | triazolam | TABLET;ORAL | 017892-002 | Nov 15, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HALCION
See the table below for patents covering HALCION around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Switzerland | 548408 | VERFAHREN ZUR HERSTELLUNG VON 8-NITRO-6-(O-HALOGENPHENYL)1-METHYL-4H-S-TRIAZOLO(4,3-A)(1,4)-BENZOBENZODIAZEPINEN. (S-triazolo (4,3-a) (1,4) benzodiazepines - as sedatives, hypnotics, tranquillisers, muscle relaxants) | ⤷ Sign Up |
| Netherlands | 8100081 | ⤷ Sign Up | |
| Israel | 33859 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
